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KAJIAN FARMAKOKINETIK DAN PENYIASATAN KESAN BAK-
ANZIOLITIK KE ATAS MITRAGININA DALAM TIKUS 
 
ABSTRAK 
 
Mitragyna speciose Korth (Rubiaceae) merupakan sejenis pokok yang berasal 
dari bahagian utara Semenanjung Malaysia dan selatan Thailand. Alkaloid utama 
dalam tumbuhan ini, iaitu mitraginina (MG), telah dilaporkan bertanggungjawab 
terhadap kebanyakan sifat farmakologinya. Dos MG yang digunakan dalam 
kebanyakan kajian farmakologi mempunyai perbezaan yang ketara, sekaligus 
menggambarkan bahawa cadangan pemilihan dos dalam pelbagai kajian yang lepas 
adalah berkemungkinan dijalankan secara empirikal iaitu tanpa asas saintifik yang 
sewajarnya. Walaubagaimanapun, kajian semasa mendedahkan bahawa terdapat 
variasi dos yang besar telah digunakan. Hal ini disebabkan oleh sifat fizikokimia MG 
tetapi variasi dos tersebut tidak pula terbatas hanya kepada sifat fizikokimia MG. 
Disebabkan penilaian farmakokinetik merupakan komponen penting dalam proses 
pemilihan dos, maka usaha diperlukan untuk menentukan sifat farmakokinetik MG 
seperti perkadaran dos, akumulasi drug, ikatan protein plasma dan taburan tisu dalam 
tikus. Kesan MG ke atas tingkahlaku yang berhubungkait dengan kegelisahan dalam 
tikus dan kemungkinan penglibatan laluan opioidergik, GABAergik dan 
dopaminergik pada kesan MG yang diperhatikan, juga diselidiki dalam kajian ini.  
Kaedah HPLC-UV bagi menentukan tahap MG dalam plasma dan tisu telah 
dibangun dan disahkan. Kaedah ini (plasma LOQ: 39 ng/ml; tisu badan LOQ: 50 
ng/ml) telah diaplikasi untuk menentukan kepekatan MG dalam sampel yang 
diperolehi daripada kajian yang melibatkan farmakokinetik, taburan tisu dan ikatan 
protein. Dalam kajian perkadaran dos, MG menunjukkan sifat farmakokinetik yang 
linear (20-40 mg/kg) manakala sifat farmakokinetik yang tidak linear telah 
 xix 
diperhatikan pada dos yang lebih tinggi daripada 40 mg/kg. Kajian ini telah 
menyediakan asas bagi pemilihan dos 20 mg/kg bagi penilaian farmakokinetik dos 
berganda MG. Pemberian MG (20 mg/kg x 2 x 7 hari) secara berulang menghasilkan 
akumulasi drug yang sederhana dalam tikus (Rac: 1.7). Parameter pendedahan MG 
selepas pemberian dos berganda boleh diramal kerana kinetik linear MG telah 
diperhatikan dalam julat dos ini (faktor kelinearan: 1.0). Dalam kajian taburan tisu, 
MG boleh ditemui terutamanya pada tisu hati, paru-paru dan ginjal manakala MG 
ditemui dengan kuantiti yang kecil dalam tisu jantung dan otak. Kewujudan MG 
dalam tisu otak tikus menunjukkan kebolehannya untuk merentasi rintangan darah 
otak (BBB) walaupun MG terikat secara tinggi pada protein plasma tikus (89-92%). 
Hal ini sekaligus mampu menjelaskan sifat psikotropik MG yang dilaporkan dalam 
laporan saintifik. Kesan bak-anziolitik MG boleh ditentukan dengan menggunakan 
ujian medan terbuka dan ujian elevated plus-maze pada tikus. Kesan-kesan ini dapat 
diperhatikan dalam tempoh sejam selepas pemberian MG secara oral pada dos 10, 20 
dan 40 mg/kg pada tikus. Kesan bak-anziolitik MG yang berlaku secara cepat 
mungkin disebabkan, tetapi tidak terbatas kepada keseimbangan yang pantas MG di 
antara plasma dan otak. Kajian ini menunjukkan bahawa MG berkemungkinan 
mempunyai kesan bak-anziolitik melalui sistem modulasi tidak langsung 
GABAergik dan dopaminergik yang dijana oleh pengaktifan reseptor opioid pada 
bahagian-bahagian otak yang terlibat dalam gerakbalas kegelisahan. 
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PHARMACOKINETICS AND INVESTIGATION 
OF THE ANXIOLYTIC-LIKE EFFECT OF MITRAGYNINE IN RATS 
 
ABSTRACT 
 
Mitragyna speciosa Korth (Rubiaceae) is an indigenous tree found in the 
Northern Malaysian Peninsula and in Southern Thailand. The principal alkaloid of 
this plant, Mitragynine (MG), has been reported to be responsible for most of its 
pharmacological properties. Doses of MG employed in most pharmacological studies 
vary greatly, which suggests that the selection of these doses was possibly carried out 
empirically without proper scientific basis. However, recent studies revealed that 
large dose variation was due but not limited, to MG physicochemical properties. 
Since pharmacokinetic evaluation is an essential component in the dose selection 
process, work was undertaken to determine MG pharmacokinetic properties such as 
dose proportionality, accumulation, plasma protein binding and tissue distribution in 
rats. The effects of MG on anxiety-related behaviours in rats and the possible 
involvement of opioidergic, GABAergic and dopaminergic pathways in the observed 
MG effects were also investigated in this study. A HPLC-UV method for the 
determination of MG levels in plasma and tissues was developed and validated. This 
method (plasma LOQ: 39 ng/ml; tissues LOQ: 50 ng/ml) was applied to determine 
MG concentrations in samples obtained from pharmacokinetic, tissue distribution 
and protein binding studies. In dose proportionality studies, MG exhibited linear 
pharmacokinetic properties (20-40 mg/kg), while non-linear pharmacokinetics were 
encountered at doses higher than 40 mg/kg. This study provided the basis to select a 
dosage of 20 mg/kg for MG multiple-dose pharmacokinetic evaluation. Repeated 
administrations of MG (20 mg/kg x 2 x 7 days) resulted in moderate drug 
accumulation in rats (Rac: 1.7). MG exposure parameters after multiple 
 xxi 
administrations were predictable since MG linear kinetics was observed in this dose 
range (linearity factor: 1.0). In the tissue distribution study, MG was mainly found in 
the liver, lung and kidney and less in heart and brain tissues. The presence of MG in 
the rat brain tissue indicated its ability to cross the blood brain barrier (BBB) despite 
its high binding to rat plasma proteins (89-92%). This may explain MG 
psychotropic properties reported in the literature. MG anxiolytic-like effects were 
determined using open-field and elevated plus-maze tests in rats. These effects were 
observed 1 hr after oral administration of 10, 20 and 40 mg/kg MG in rats. The early 
anxiolytic-like effects of MG may be due, but not limited, to the rapid equilibrium of 
MG between plasma and brain. This study showed that MG had possibly exerted its 
anxiolytic-like effects by indirect modulation of GABAergic and dopaminergic 
systems through the activation of opioid receptors in brain regions involved in 
anxiety. 
 
 
 1 
CHAPTER ONE 
INTRODUCTION 
 
1.1 Background  
 
Mitragyna speciosa Korth (Rubiaceae) is an evergreen tree native to 
Southeast Asian countries. In Malaysia, it is commonly known as “Ketum”. Its leaves 
were traditionally used by the locals to relieve pain and mitigate morphine 
withdrawal symptoms (Burkill, 1935, Watanabe et al., 1997). The plant is prohibited 
in Malaysia under the Third Schedule of the Poisons Act (1952) due to its narcotic 
properties; however recent studies have reported its wide use in the northern states of 
this country such as Kedah and Perlis. Villagers in these states use the Ketum drink 
to control opioid withdrawal symptoms as it is easily available and cheaper than 
other substances of abuse it is available over the internet and has been used as self-
treatment in managing opiate withdrawal symptoms, alcohol withdrawal and chronic 
pain (Babu et al., 2008, Boyer et al., 2008, Boyer et al., 2007).   
 
Over 25 alkaloids have been isolated from the mature leaves of this plant with 
mitragynine (MG) being the most dominant active alkaloid (Chittrakarn et al., 2008, 
Shellard, 1974). Several studies were conducted to determine the pharmacological 
and toxicological properties of MG in laboratory animals. However, MG doses 
employed in toxicity (477 to 920 mg/kg), behavioural (33 to 200 mg/kg) and 
pharmacokinetic studies (20 to 50 mg/kg) varied largely (Idayu et al., 2011, Idid et 
al., 1998, Janchawee et al., 2007, Parthasarathy et al., 2010, Sabetghadam et al., 
2010, Sabetghadam et al., 2013b). The wide range of MG doses employed in these 
 2 
studies suggests that the selection of these doses was possibly carried out empirically 
without proper scientific basis. It is also important that pre-clinical studies should 
preferably being conducted at a dose level whereby a meaningful translation of 
animal data for possible human interpretation could be derived. 
 
Of late, Ramanathan et al. (2015) reported the physicochemical properties of 
MG. The study described MG as a poor water soluble compound, acid labile, with  
basic and lipophilic nature (Ramanathan and Mansor, 2015). Later, the investigators 
associated these physicochemical properties of MG to the large varied MG dose 
employed in pre-clinical studies. But this rational should be further substantiated by 
knowledge of the MG plasma protein binding, tissue distribution and accumulation 
of the compound after repeated doses using suitable animal models. Further to this, 
all the reported MG pre-clinical studies provided information only relating to its 
toxicology and pharmacological effects without estimating the MG concentrations in 
plasma and tissues. Similarly in a most recent study in rodents, MG was reported to 
possess potential threat of abuse at medium and high doses of the  pure compound 
(10, 30 mg/kg); but regrettably for a psychoactive drug like MG this observation was 
not correlated to MG concentrations in plasma or brain tissues (Yusoff et al., 2014). 
One immediate possible reason for this could be due to the lack of an accurate and 
sensitive analytical method to determine the concentration of MG in tissues such as 
brain, liver, lungs and other bodily organs. There are a few MG analytical methods 
reported in literature however these methods are limited to biological fluids such as 
plasma and serum (Parthasarathy et al. 2010, de Moraes et al. 2009, Janchawee et al 
.2007, Vuppala et al. 2011). Therefore determination of the tissue distribution, 
accumulation and protein binding properties of MG would provide the basis to 
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devise a more realistic  study design for future MG pre-clinical evaluations (Hazim et 
al., 2011, Idayu et al., 2011, Khor et al., 2011). However before work is undertaken 
to determine the distribution, accumulation and binding properties of MG in animal 
models, the selection of dose at which MG exhibits linear pharmacokinetic is 
essentially important. This is because, administration of drug at doses higher than 
this range could result in a non-proportional changes in its plasma concentration due 
to saturation of one or more of the processes of absorption, distribution, metabolism 
and elimination. Saturation of these processes could also occur when repeated doses 
of a drug are administered. This could lead to plasma concentrations significantly 
higher than expected which might result in toxicity or lead to plasma drug 
concentrations not within the target range. As a result, misinterpretation of pre-
clinical findings could occur which eventually led to wrong conclusions. In addition 
to this as mentioned earlier in this thesis, the selected dose for animal testing should 
also preferably reflect a human equivalent dose for notable interpretation of the 
animal data to clinical situation since MG is gaining more attention as a potential 
alternative or adjunct drug in treating addiction and chronic pain.  
 
With reference to MG dose selection, most reported pharmacokinetic studies 
(20-50 mg/kg)  were  carried out on trial and error  basis  and no dose-finding studies 
were included in their study design (de Moraes et al., 2009, Janchawee et al., 2007, 
Parthasarathy et al., 2010, Philipp et al., 2009). There are no literature reports on the 
lowest MG oral dose given to animals for possible detection of the drug in plasma 
using either HPLC or LC-MS/MS analytical methods. MG dose escalating studies in 
animals are also lacking in literature as this is important to demonstrate MG dose-
linearity. With regard to MG toxicity, the drug was found safe in rats after repeated 
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administration of lower dose (1 and 10 mg/kg) but not at higher dose (100 mg/kg) 
(Sabetghadam et al., 2013a). At present there are no data on the distribution and 
accumulation profile of MG available in the literature to precisely explain its 
pharmacological responses and organ toxicity reported in pre-clinical studies.  
  
With regard to MG pharmacological properties, MG has been shown to 
produce an anti-depressant effect, decrease novel environment stress in animals and 
attenuated stress-related behaviours in morphine-withdrawn zebrafish (Hazim et al., 
2011, Idayu et al., 2011, Khor et al., 2011). The drug is known to exert its effects 
through the activation of μ, κ and opioid receptors (Matsumoto et al., 1996b, 
Taufik Hidayat et al., 2010a, Watanabe et al., 1997, Yamamoto et al., 1999).  
 
With respect to anxiety-related behaviour in animals, in general opioid 
agonists are known to act via interactions among opioidergic, GABAergic and 
dopaminergic systems in the brain (Klitenick et al., 1992, Sasaki et al., 2002). In the 
case of MG as a psychoactive compound, there are no proper documented studies on 
its anxiolytic effect in animals that have been reported. For this reason, another 
interesting part in this thesis also deals with systemic studies of MG anxiolytic effect 
in rats. The determination of MG tissue distribution and protein binding properties 
may further explain the anxiolytic properties of MG in rats. 
 
 
 
 
 5 
It is important to note that, for any pharmacokinetic, tissue distribution or 
protein binding studies to be successful development of a simple sensitive and 
selective analytical method for assay the drug in biological samples are imperative.  
Further to this the selection of appropriate MG dose in order to obtain a reliable and 
accurate pharmacokinetic, tissue distribution and protein binding  properties of MG 
is equally important when interpreting MG pre-clinical studies or inferring the data 
for clinical situation. On the other hand, MG toxicity, analgesic and basic 
pharmacokinetics properties have been reported in the literature but studies on 
anxiolytic effect of MG is still lacking; and with the establishment of these MG 
biological properties the reported MG pharmacological properties and its anxiety-
related behaviour in rats could be better understood. To achieve this, the following 
objectives were undertaken in this thesis: 
 
 
1. To develop and validate a HPLC-UV method using simple protein 
precipitation step for the assay of MG in plasma and tissues (liver, kidney, 
lung, heart and brain) for application in pharmacokinetic studies. 
 
2. To conduct dose-proportionality and multiple dose pharmacokinetic studies 
to determine the dose range at which MG exhibit linear pharmacokinetic 
profile as well as MG disposition kinetic and its accumulation properties 
following repeated administrations to rats. 
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3. To conduct tissue distribution and plasma protein binding studies in order to 
determine the distribution and accumulation profile of MG into rat tissues 
following single oral dose administration and to estimate the extent to which 
MG binds to rat plasma proteins. 
 
4. To determine the effects of MG on anxiety-related behaviours in rats using 
open-field and elevated plus-maze tests and to evaluate the involvement of 
opioidergic, GABAergic and dopaminergic systems in the observed effects of 
MG.  
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CHAPTER TWO 
LITRERATURE REVIEW 
 
 
 
2.1 Herbal medicines 
 
Herbal medicines have been used to treat various ailments and to maintain 
good health since the earliest days of mankind. The use of herbal remedies has been 
increasing markedly over the past decades as herbs are cheap and have fewer side-
effects than some conventional medications. Raw and partly-processed medicinal 
plants are usually exported from developing countries such as China, India, Mexico, 
Bulgaria, Chile and Egypt. The main processing of these plants takes place in 
developed countries such as the US, Germany, France and Republic of Korea where 
plant products are either sold in domestic markets or exported to other countries 
(Williamson and MacTavish, 2008). During the period 1991 to 2003, China 
contributed to one-third of the total global exportation of medicinal plants by 
exporting an average of 150,600 tons/ year valued at US$ 266 million. On the other 
hand, European countries such as Germany, France, Italy, Spain and the UK 
contributed to one-third of the global import market by importing the average of 
96,300 tons/year valued at US$ 256 million. During the same period, Malaysia 
imported an average of 7,050 tons of medicinal plants with the value of US$ 
38,685,400/year (Lange, 2006). The World Health Organization reported that 
approximately 70-80% of the world population relies on herbal medicines for their 
primary health care (Akerele, 1993, Farnswaorth and Soejatro, 1991). In the US, one 
third of the population was reported to use herbal medicines in 1997. In the same 
year, the sales of herbal medicines in US were estimated to be US$ 3.24 billion 
(~RM12.3 billion).  
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The market of herbal medicines in Malaysia was estimated to be RM 2.0 
billion in 1997; when Malaysians expenditure on herbal medicines reached about 
RM 91.00 per person per year compared to that of Americans which was 
approximately RM 45.00 per person per year taking into account populations of 22 
and 273 million respectively (Hussin, 2001). An earlier study also reported that 
17.1% of Malaysians use herbal medicines to treat different illnesses while 29.6% of 
them rely on herbs for health maintenance (Mahmud, 1993).  
 
Over 35,000 plant species have been used in traditional medicine worldwide 
(Farnswaorth and Soejatro, 1991). In 1966, Burkill and colleagues reported the use of 
more than 1000 plant species in the folk medicine in the Malay Peninsula (Burkill et 
al., 1966). Several studies were conducted to record the traditional knowledge on 
medicinal plants in different states of Malaysia such as Negri Sembilan, Pahang, 
Terengganu and Johor  (Ong et al., 2011a, Alsarhan et al., 2012, Eswani et al., 2010, 
Ong et al., 2011b). The exact number of medicinal plant species, the disease each 
plant is supposed to alleviate and the method of preparation varied from one study to 
another as traditional knowledge is not well documented and verbally passed through 
the generations. Mitragya speciosa Korth is one of the Malaysian medicinal plants 
used by local people to treat various ailments. Mitragya speciosa (M. speciosa) 
leaves contain more than 25 alkaloids and mitragynine (MG) is the most abundant 
alkaloid, responsible for many of the plant’s pharmacological effects. 
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2.2 Mitragyna speciosa Korth 
 
2.2.1 Plant description  
 
M. speciosa Korth (Rubiaceae) is a tropical evergreen tree indigenous to 
Southeast Asian countries such as Malaysia and Thailand. In Malaysia, it is 
commonly known as “Biak-Biak”, “Bia”, “Kutum” or “Ketum” and is native to the 
northern and west coast part of the Malaysia peninsular. It is also found in the central 
and southern regions of Thailand and is known as “Kratom”, “Katawn”, “Tawm” or 
“Thom”. This plant was first described by a Dutch botanist Pieter Korthals, who 
named the genus of this plant “Mitragyna” as the shape of the first stigmas he 
examined resembled a bishop’s mitre (Shellard, 1974).  
 
Ketum tree (Fig. 2.1) can grow up to 50 feet (15 meters) tall. It grows heavily 
in high humidity areas rich with humus and is sensitive to drought and severe 
coldness. The tree can be characterized by its globular yellow flowering head each 
contain up to 120 florets. The fruit is a capsule containing numerous small flat seeds. 
The leaves of this tree are dark glossy green which grow up to 7 inches in length and 
4 inches in width. Two types of M. speciosa can be distinguished based on the colour 
of veins in the leaf, either red or white-greenish (Fig 2.1 & 2.2) (Suwanlert, 1975). 
The red-veined leaves are known for their high MG content compared to the white-
greenish-veined leaves (Hanapi et al., 2013). Therefore, MG used in this study was 
isolated from fresh red-veined M. speciosa leaves.  
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Figure 2.1: Mitragyna speciosa tree.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Red-veined Mitragyna speciosa leaf.  
1:1.2 cm 
1:100 cm 
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2.2.2 Phytochemistry of Mitragyna speciosa  
 
Over 25 alkaloids have been isolated from the leaves of this plant. The main 
indole alkaloids found in the young leaves of Malaysian and Thai plants were MG 
and its derivatives speciogynine, speciociliatine, paynantheine and 7-
hydroxymitragynine. New types of alkaloids such as 3,4-dehydromitragynine, 
mitragynaline, corynantheidaline, mitragynalinic acid, corynantheidalinic acid and 7-
hydroxyspeciociliatine were also isolated from the fresh leaves and fruits of 
Malaysian M. speciosa (Houghton et al., 1991, Kitajima et al., 2006). MG was found 
to be the most dominant alkaloid in the leaves of this plant and is believed to 
contribute to its pharmacological effects (Figure 2.3). It was first isolated by Hooper 
(1907) and later by Field (1921) who named the alkaloid (Shellard, 1974). In 1964, 
Zacharias and colleagues first determined the structure of MG using x-ray 
crystallography (Zacharias et al., 1965). MG structure is related to those of 
yohimbine and voacangine; its molecular formula is C23H30N2O4 and has a molecular 
weight of 398.5 (Hassan et al., 2013, Takayama et al., 1998). MG melting point is 
between 102°C-106°C and it has a boiling point of 239°C-240°C. Physically, MG is 
a white yellowish amorphous powder soluble in alcohol, chloroform, acetic acid and 
oily substance. The UV spectrum of methanol solution of MG shows absorbance 
bands between the wavelength of 226 and 292 nm (Barceloux, 2012, Macko et al., 
1972, Zacharias et al., 1965). MG was first synthesized by Takayama and colleagues 
(Takayama et al., 1995) and MG synthesis pathways were reported by Ma and 
colleagues (2009). The total alkaloid content of M. speciosa leaves varies from 0.5% 
to 1.5%. Green leaves contain about 0.2% MG with the average green and dry leaf 
weighing about 1.7 grams and 0.43 grams respectively. Although MG  is the major 
constituent of Malaysian and Thai plants, the yield obtained from the total alkaloid 
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extract of Malaysian M. speciosa leaves (12%) was much less than that of the Thai 
plant (66%). These quantitative variations in MG content may be due to differences 
in geographic origin, plant age and harvest season (Barceloux and Palmer, 2012, 
Takayama, 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: The Chemical structure of mitragynine (αE, 2S, 3S, 12bS)-3-ethyl 
1,2,3,4,6,7,12,12b-octahydro-8-methoxy-α(methoxyme-thylene)-indolo[2,3-a] quino-
lizine-2-acetic acid methyl ester. Adapted from Chemical Abstract Service (CAS).  
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2.2.3 Traditional use 
 
In Malaysia, M. speciosa leaves have been widely used as a traditional 
medicine for centuries. The leaves were chewed, smoked or drunk as a suspension by 
local people to enhance work tolerance under intense tropical heat (Grewal, 1932, 
Jansen and Prast, 1988). In addition, the leaves were also used to relieve pain, reduce 
coughing, alleviate diabetes, diarrhoea, and to mitigate morphine withdrawal 
symptoms (Watanabe et al., 1997). Administration of M. speciosa leaves has been 
shown to produce a stimulant effect at low doses and sedative and analgesic effects 
at the higher doses in humans and laboratory animals therefore suggesting the 
presence of dual opioid properties (Macko et al., 1972, Suwanlert, 1975).  
 
 
2.2.4 Pharmacological effects of Mitragyna speciosa and mitragynine 
 
Several studies have been conducted to investigate the pharmacological 
effects of M. speciosa leaves extracts, MG and it derivatives. The effects of the 
methanolic extract of M. speciosa leaves on the rat gastrointestinal tract were 
investigated by Chittrakarn and colleagues (2008). Administration of the methanolic 
extract significantly reduced defecation frequency, total score, fecal weight and 
intestinal transit in castor oil-induced diarrheal rats. These findings supported the 
traditional use of M. speciosa leaves to treat diarrhea (Chittrakarn et al., 2008). In 
another study, incubation of rat L8 muscle cell with various concentrations of water, 
methanolic, alkaloid extracts of M. speciosa leaves and MG respectively showed an 
increase in the rate of glucose uptake and the concentration of glucose 
transporters per unit of muscle protein. This observation supported the use of M. 
speciosa leaves extracts in folk medicine to alleviate diabetic patients (Purintrapiban 
et al., 2011). The methanolic extract of M. speciosa leaves was also evaluated for its 
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acute and chronic anti-inflammatory effects using carrageenan-induced paw edema 
and cotton pellet-induced granuloma tests respectively. Intraperitoneal administration 
of the methanolic extract of M. speciosa leaves inhibited the development of paw 
edema with a maximal inhibition during the first 3h following the injection of 
carrageenan into the subplantar region of the rat hind paw. The administration of the 
extract for seven days significantly reduced granulomatous tissue formation in the 
chronic test (Shaik Mossadeq et al., 2009). Similarly, MG exhibited anti-
inflammatory activity through the inhibition of cyclooxygenase 2 (COX-2) mRNA 
and protein expression and prostaglandin E2 (PGE2) formation in macrophage cells 
(Utar et al., 2011).  
 
The administration of M. speciosa leaves extracts or MG has shown to 
produce antinociceptive effects in laboratory animals. The administration of the 
methanolic and alkaloid extracts of M. speciosa leaves in mice prolonged the latency 
of nociceptive responses in hotplate test (Reanmongkol et al., 2007). These 
antinociceptive effects were further investigated using acetic-acid-induced writhing 
test and formalin test. Intraperitoneal administration of the methanolic extract of M. 
speciosa leaves significantly inhibited writhing responses and pain sensation in rats 
(Shaik Mossadeq et al., 2009). The antinociceptive effects of several M. speciosa 
leaves extracts were compared to that of morphine using hot plate and tail flick tests. 
The alkaloid, methanolic and the aqueous extract of M. speciosa leaves were orally 
administered to Sprague-Dawley rats. Administration of these extracts as well as 
morphine significantly prolonged the latency of nociceptive responses in both tests. 
These effects were significantly reversed by naloxone, a competitive antagonist at -, 
-, and-opioid receptors suggesting the involvement of these receptors in the 
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observed antinociceptive effects of M. speciosa leaves extracts (Sabetghadam et al., 
2010). An intraperitoneal and intracerebroventricular administration of MG produced 
antinociceptive effects in mice tested in tail-pinch and hot-plate tests. These effects 
were significantly reversed by pretreatment with naloxone suggesting the 
involvement of supraspinal opioid systems in the antinociceptive effect of MG 
(Matsumoto et al., 1996b). MG has also shown to suppress the electrically stimulated 
contraction of guinea-pig ileum and mouse vas deferens through the activation of μ- , 
- and -opioid receptors (Matsumoto et al., 2005b, Watanabe et al., 1997). The 
binding of MG to opioid receptors has been further examined using radioligand 
binding assay. MG has been shown to activate opioid receptors with high affinity to 
- and - followed by -opioid receptor subtypes (Boyer et al., 2008, Taufik Hidayat 
et al., 2010b). A minor constituent of M. speciosa leaves, 7-hydroxymitragynine has 
been shown to produce a 46-fold more potent antinociceptive effects compared to 
MG (Matsumoto et al., 2005a). Oral and subcutaneous administration of 7-
hydroxymitragynine has also been shown to produce a more potent analgesic effect 
compared to morphine in the hot-plate and tail-flick tests in mice (Matsumoto et al., 
2006). The potent analgesic effects of 7-hydroxymitragynine could be due its higher 
lipophilicity (log p: 1.3) compared to morphine (log p:  0.9) which enhances the drug 
penetration across the BBB and its CNS activity (Hansen et al., 2012). This effect 
was significantly reversed by pretreatment with naloxone suggesting the involvement 
of -opioid receptors in the observed effects of 7-hydroxymitragynine (Takayama, 
2004). In addition, the involvement of - and -supraspinal opioid receptors in the 
antinociceptive effects of 7-hydroxymitragynine was also reported in earlier studies 
(Matsumoto et al., 2006, Matsumoto et al., 2005a).  
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Several studies have reported the neurophysiological effects of M. speciosa 
extracts and MG. Grewal (1932) suggested two ways of MG action on the central 
nervous system in laboratory animals. The first way are the effects on the autonomic 
nervous system which consist of facilitation of the passage of impulses affecting both 
the crania-sacral and sympathetic divisions. The second way are the effects on the 
central nervous system which consist of an excitation of the motor centres in the 
medulla (Grewal, 1932). Administration of the aqueous and alkaloid extracts of M. 
speciosa leaves has been shown to produce antidepressant-like effects in mice tested 
in forced-swim and tail suspension tests (Kumarnsit et al., 2007a, Kumarnsit et al., 
2007b). Similarly, intraperitoneal administration of MG has also been shown to 
produce antidepressant-like effects and decrease the release of corticosterone in mice 
suggesting the role of neuroendocrine hypothalamic-pituitary-adrenal axis in 
modulating MG effects (Idayu et al., 2011). In our laboratory, acute oral 
administration of MG to mice has also been shown to enhance exploratory 
behaviours by mitigating stress to a novel Y-maze environment (Hazim et al., 2011). 
Considering the antidepressant and stress-mitigating effects of MG in laboratory 
animals, this work was undertaken to evaluate the effect of MG on anxiety-related 
behaviours in rats using open-field and elevated plus-maze. The possible 
involvement of opioidergic, GABAergic and dopaminergic systems in the observed 
effects of MG was also determined.   
 
2.2.5 Mitragyna speciosa legal status  
 
M. speciosa plant has been prohibited in Thailand since 1943. In 1970 the 
Thai government placed M. speciosa  under Schedule 5 of the Thai Narcotic Act 
whereby existing trees need to be cut down and it is illegal to buy, sell, import or 
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possess it (Hassan et al., 2013). In Malaysia, the plant has been prohibited under the 
Third Schedule of the Poisons Act (1952). Under this Act “the planting of the tree is 
not an offence, and enforcement agencies have no authority to fell the trees. The 
maximum penalty for possessing or selling ketum leaves or other ketum preparations 
such as drinks and teas containing mitragynine is a fine of RM 10,000, a four-year 
jail sentence or both” (Chan et al., 2005). M. speciosa, MG and 7-
hydroxymitragynine are considered as controlled drugs in many EU countries such as 
Denmark, Poland and Sweden. In countries such as Australia and Myanmar, M. 
speciosa and MG are under the control of Narcotics Laws. M. speciosa and MG are 
not listed as controlled substances in the US, UK and Germany however they are 
considered as serious drugs (EMCDDA, 2012).  
 
2.2.6 The use of Mitragyna speciosa leaves to manage opioid withdrawal 
symptoms 
The use of M. speciosa leaves is still uncontrolled in some western societies 
where it is easily available over the internet. In recent years, this plant has been used 
as self-treatment of opioid withdrawal symptoms, alcohol withdrawal and chronic 
pain (Babu et al., 2008, Boyer et al., 2008, Boyer et al., 2007). Several studies 
reported the use of M. speciosa leaves to substitute opium in the treatment of opioid 
addiction in Malaysia and Thailand. In recent years, this plant has become controlled 
or illegal in these countries. However, its use is widely reported by locals in villages 
where it is easily available and cheaper than other substances of abuse. 
Vicknasingam et al (2010) reported the use of ketum drink in Northern Malaysian 
peninsular to reduce addiction to other drugs. The study revealed that ketum users 
consume an average of 3 medium-sized glasses (each 250 ml) of ketum drink to 
manage opioid withdrawal symptoms (Vicknasingam et al., 2010). Another study by 
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Ahmad and Aziz (2012) reported the use of  ketum  drink in the northern states of 
Kedah and Perlis to treat opioid withdrawal, build up physical stamina and 
endurance, relieve pain and improve sexual performance (Ahmad and Aziz, 2012). 
Based on this observation, the MG content in ketum drink obtained from various 
geographical and socio-economic backgrounds was determined by Parthasarathy et 
al. (2013). This further provided the basis to predict the standard daily dose of MG 
consumed by ketum users. The estimated dose consumed was in the range of 0.3 to 
5.7 mg/kg body weight. Using the human-rat dose equivalent table, the 
corresponding MG dose in rats was in the range of 1.85-35.15 mg/kg (Reagan-Shaw 
et al., 2008). The given MG dose range was considered while selecting the 
appropriate MG dose regimen for the current pharmacokinetic, tissue distribution and 
behavioural studies. 
 
2.3 Anxiety  
 
Anxiety is a natural adaptive reaction induced in animals and humans in 
anticipation of actual or potential threat. This reaction is accompanied by marked 
behavioural and physiological responses which evolve to help the individual cope 
with various challenges and stressful events (Steimer, 2002).  
 
2.3.1  The physiology of anxiety  
Behavioual responses associated with anxiety include a range of defensive or 
adaptive behaviours. The development of these behaviours depend on the context 
and the behavioural repertoire of the species (Steimer, 2002). When the threat 
causing anxiety is escapable, active emotional coping strategies are used. This type 
of active response was originally described by Cannon as “fight or flight” response 
(Cannon, 1963). This response is characterized by the activation of sympathetic 
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nervous system and the subsequent release of epinephrine, norepinephrine and 
cortisol from the adrenal gland (Brick and Erickson, 2009). The role of the 
sympathetic response is to make an automatic, internal adjustment in the body 
without a concious effort by the individual. Sympathetic activation together with the 
release of epinephrine, norepinephrine and cortisol orchestrates changes in heart rate, 
blood pressure, blood glucose level, body temperature and sweat gland secretion to 
prepare the individual for violent activity (Levitt, 1967). When the threat causing 
anxiety is inescapable, passive emotional coping strategies such as quiescence, 
immobility and decreased responsiveness to the environment are used (Bandler et al., 
2000). Passive responses were first described by Engel and Schmale (1972) as a 
conservation-withdrawal strategy which is characterized by autonomic inhibition 
(hypotension and bradychardia), activation of the hypothalamopituitary-adrenal axis 
and increased glucocorticoid secretion (Steimer, 2002). In 1929, Cannon and Brad 
demonstrated that physiological reactions and emotional experiense arise 
simultanously, mediated by two lower brain centers, thalamus and the 
hypothhalamus. In 1937, Papez suggested a neural pathway connecting the 
hypothalamus and cortex as the emotional system of the brain. In 1952, Paul D. 
MacLean reported the central role of amygdala in modulating emotional responses. 
He expanded Papez ideas by adding more stractures to Papez circuit and named the 
modified version of the circuit as the limbic system (Levitt, 1967). The limbic system 
is a set of struactures that controls emotional behviour and motivational derives 
(Figure 2.4). It is located on both sides of the thalamus, right under the cerebelum. 
The limbic system is composed of the hypothalamus surrounded by other subcortical 
stractures of the limbic system including the septum, the paraolfactory area, the 
anterior nucleus of the thalamus, portions of the basal ganglia, the hippocampus and 
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the amygdala. Surrounding the subcortical limbic areas is the limbic cortex 
composed of orbitofrontal area, subcallosal gyrus, cingulate gyrus, parahippocampal 
gyrus and uncus (Guyton and Hall, 2006). The Reticular Activating System (RAS) is 
a part of brain centered in brain stem. The primary role of RAS is to control the 
sleep-waking continuum. However, with the cerebral cortex, RAS is involved in a 
feedback-control operation to maintain the optimal stimulation level. This implies 
that sensations reaching the cerebral cortex are constantly fed back to the RAS. 
When the frequency of these impulses increase significantly, RAS send inhibitory 
impulses back to the cortex, damping its activity. It was therefore suggested that the 
experience of anxiety is a result of a weakining of the inhibitory function of RAS 
resulting in too many facilitative impulses to be discharged to the cortex, leading to 
an arousal level beyond the normal (Malmo, 1957).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: The limbic system, figure reproduced with permission from Pearson 
Education (2012).  
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2.3.2  Neurotransmitter systems involved in anxiety  
Several neurotransmitter systems are involved in the modulation of anxiety 
behaviours. The main neurotransmitter systms implicated in anxiety are the 
GABAergic, serorotonergic and dopaminergic system.  
 
2.3.2.1  The GABA system 
γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter of the 
mammalian central nervous system (Durant et al., 2010). GABA acts via two main 
types of receptors, the fast-acting ion gated receptors (GABA-A and GABA-C) and  
the slower-acting G-coupled GABA-B receptor (Bormann, 2000). GABA-A receptor 
is the most abundant GABA receptor in the brain. GABA-A receptors play a crucial 
role in regulating the excitatory tone of many neurons including dopaminergic, 
cholinergic and serotonergic (Fritschy et al., 1992, Gao et al., 1995). In addition, 
earlier studies provided strong support for the role of GABA-A receptors in 
modulating anxiety-related behaviours (Lydiard, 2003, Mohler, 2012). GABA-A 
receptor consists of five protein subunits 2, 2 and 1 subunits. These subunits are 
arranged like a rosette around a central pore (Nayeem et al., 1994). GABA acts as an 
agonist at the receptor complex. Binding of GABA at the interface between  and 
subunits triggers conformational changes, which enhance the influx of chloride 
ions into the post-synaptic neuron through the central pore. This results in a state of 
hyperpolarisation and reduces neuron excitability (Nutt, 2006). Benzodiazepines 
(BDZs) are a class of tranquilizer drugs used to treat anxiety, seizures and insomnia. 
BDZs bind at the interface between  and  subunits of GABA-A receptor resulting 
in channel opening and influx of chlorine ion (Olsen et al., 2004). BDZs augment the 
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response of GABA-A receptor to endogenous GABA by reducing the concentration 
of GABA needed to cause chloride channel opening (Nutt and Malizia, 2001).    
 
2.3.2.2  The serotonergic system 
Serotonergic neurones arise from the median and dorsal raphe nuclei in the 
brainstem and project throughout the forebrain (Durant et al., 2010). Serotonin (5-
hydroxytryptamine or 5-HT) is synthesized from the essential amino acid tryptophan 
(Richard et al., 2009). Following the release of 5-HT into the synaptic cleft, 5-HT is 
transported back into the pre-synaptic neuron by serotonin transporters (Sangkuhl et 
al., 2009). Although more than 10 serotonin receptors were identified; 5-HT-1A has 
particularly been linked to anxiety disorders (Durant et al., 2010). Nowadays, 
selective serotonin reuptake inhibitors (SSRIs) have been effectively used to treat 
anxiety disorders. These serotonergic agents inhibit serotonin reuptake process and 
therefore enhance serotonin level in the synapses and reduce anxiety behaviours 
(Benitez et al., 2008).  
 
2.3.2.3 The dopaminergic system  
Dopamine is synthesised from the amino acid tyrosine. The main 
dopaminergic pathways are the nigrostriatal (associated with motor control), 
tuberoinfundibular pathway (regulates the release of prolactin from the pituitary 
gland), mesolimbic pathway (associated with reward and cognitive behaviours) and 
mesocortical pathways (involved in cognitive control, motivation and emotional 
responses) (Durant et al., 2010). Although five different dopamine receptors (D1-D5) 
were identified, D1 and D2 dopamine receptors have been shown to modulate 
anxiety-related behaviours (Rodgers et al., 1994, Schneier et al., 2000, Schneier et 
 24 
al., 2008). In addition, earlier studies have also reported that dopamine deficiency is 
strongly associated with social anxiety disorders (Berrios et al., 1995, Liebowitz et 
al., 1992, Van der Wee et al., 2008). 
 
2.3.3  Anxiety disorders 
Anxiety can become a pathological disorder when it is so intense, prolonged 
and interferes with normal life (Gross and Hen, 2004). The American Psychiatric 
Association divided anxiety disorders into five main types including panic disorder, 
obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety 
disorder and phobias such as specific phobia, social phobia and agoraphobia (APA, 
2010).  Panic disorder is characterized by unexpected and repeated panic attacks. The 
exact cause of these disorders is unknown; however several physical and 
psychological factors may contribute to this disorder such as traumatic life 
experience, genetic link, and imbalance of brain neurotransmitters (Kim et al., 2012). 
Obsessions are persistent upsetting and irrational thoughts that cause great anxiety 
which can not be controlled through reasoning. Compulsions are repeated behaviours 
used to minimize these obsessions (Montgomery and Morris, 1994). Post-traumatic 
stress disorder is caused by distressing events. People with this disorder repeatedly 
retrive the traumatic event through flashbacks and nightmares (Mueller et al., 2005). 
On the other hand, generalized anxiety disorder tends to permeate most of people’s 
life rather than being focused on particular part (Montgomery and Morris, 1994).  
Specific phobia is an excesssive fear of an object or situation that actually poses little 
or no threat such as height, tunnels and injuries involving blood (NIH, 2009). Social 
phobia is a fear of being mocked or criticized by unfamiliar people in situations such 
as public speaking or eating in front of others (Wittchen et al., 2011). Agoraphobia is 
